Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to “Buy” Rating by StockNews.com

StockNews.com cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a report released on Thursday morning.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $31.76 on Thursday. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 29.68 and a beta of 0.90. The firm has a 50-day moving average of $37.19 and a 200-day moving average of $35.34.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. Insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SUPN. Mirae Asset Global Investments Co. Ltd. raised its holdings in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Supernus Pharmaceuticals by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,599 shares of the specialty pharmaceutical company’s stock valued at $330,000 after acquiring an additional 4,140 shares during the period. Rice Hall James & Associates LLC increased its holdings in shares of Supernus Pharmaceuticals by 7.6% during the third quarter. Rice Hall James & Associates LLC now owns 540,788 shares of the specialty pharmaceutical company’s stock worth $16,862,000 after purchasing an additional 38,202 shares during the period. Stephens Investment Management Group LLC increased its holdings in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares during the period. Finally, James Investment Research Inc. increased its holdings in shares of Supernus Pharmaceuticals by 39.8% during the third quarter. James Investment Research Inc. now owns 17,644 shares of the specialty pharmaceutical company’s stock worth $550,000 after purchasing an additional 5,022 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.